Veru (NASDAQ:VERU) Price Target Lowered to $9.00 at Oppenheimer

Veru (NASDAQ:VERU – Get Rating) had its target price cut by stock analysts at Oppenheimer from $14.00 to $9.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price objective indicates a potential upside of 383.87% from the company’s current price.

Separately, HC Wainwright dropped their price objective on Veru from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, February 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $28.33.

Veru Trading Up 1.1 %

Shares of VERU opened at $1.86 on Wednesday. Veru has a 12 month low of $1.76 and a 12 month high of $24.55. The stock’s 50 day moving average is $4.61 and its two-hundred day moving average is $7.79. The firm has a market cap of $150.03 million, a P/E ratio of -1.30 and a beta of -0.15.

Institutional Trading of Veru

Institutional investors have recently made changes to their positions in the company. Level Four Advisory Services LLC boosted its stake in shares of Veru by 6.6% in the third quarter. Level Four Advisory Services LLC now owns 98,167 shares of the company’s stock worth $1,131,000 after acquiring an additional 6,077 shares during the last quarter. Capital Fund Management S.A. purchased a new position in Veru during the third quarter worth approximately $4,350,000. Harvest Investment Services LLC purchased a new position in Veru during the third quarter worth approximately $551,000. SG Americas Securities LLC lifted its position in Veru by 653.4% during the third quarter. SG Americas Securities LLC now owns 85,980 shares of the company’s stock worth $990,000 after buying an additional 74,567 shares in the last quarter. Finally, Northeast Financial Consultants Inc purchased a new position in Veru during the third quarter worth approximately $187,000. 48.87% of the stock is owned by institutional investors and hedge funds.

About Veru

(Get Rating)

Veru, Inc is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT.